PMID- 33535013
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220531
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 23
IP  - 7
DP  - 2021 Jul
TI  - Predictive Low-Glucose Suspend Necessitates Less Carbohydrate Supplementation to 
      Rescue Hypoglycemia: Need to Revisit Current Hypoglycemia Treatment Guidelines.
PG  - 512-516
LID - 10.1089/dia.2020.0619 [doi]
AB  - Current guidelines recommend 15-20 g of carbohydrate (CHO) for treatment of mild 
      to moderate hypoglycemia. However, these guidelines do not account for reduced 
      insulin during suspensions with predictive low-glucose suspend (PLGS). We 
      assessed insulin suspensions, hypoglycemic events, and CHO treatment during a 
      20-h inpatient evaluation of an investigational system with a PLGS feature, 
      including an overnight basal up-titration period to activate the PLGS. Among 10 
      adults with type 1 diabetes, there were 59 suspensions; 7 suspensions were 
      associated with rescue CHO and 5 with hypoglycemia. Rescue treatment consisted of 
      median 9 g CHO (range: 5-16 g), with no events requiring repeat CHO. No rescue 
      CHO were given during or after insulin suspension for the overnight basal 
      up-titration. To minimize rebound hyperglycemia and needless calorie intake from 
      hypoglycemia overtreatment, updated guidance for PLGS systems should reflect 
      possible need to reduce CHO amounts for hypoglycemia rescue associated with an 
      insulin suspension. The clinical trial was registered with ClinicalTrials.gov 
      (NCT03890003).
FAU - Pinsker, Jordan E
AU  - Pinsker JE
AD  - Sansum Diabetes Research Institute, Santa Barbara, California, USA.
FAU - Bartee, Amy
AU  - Bartee A
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Katz, Michelle
AU  - Katz M
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Lalonde, Amy
AU  - Lalonde A
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Jones, Richard
AU  - Jones R
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Dassau, Eyal
AU  - Dassau E
AD  - Eli Lilly and Company, Cambridge, Massachusetts, USA.
FAU - Wolpert, Howard
AU  - Wolpert H
AD  - Eli Lilly and Company, Cambridge, Massachusetts, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03890003
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210218
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 1/complications/drug therapy
MH  - Dietary Supplements
MH  - Humans
MH  - *Hypoglycemia/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Insulin Infusion Systems
PMC - PMC8252907
OTO - NOTNLM
OT  - Carbohydrate
OT  - Predictive low-glucose suspend
OT  - Type 1 diabetes
OT  - hypoglycemia
COIS- J.E.P. reports receiving grant support, provided to his institution, and 
      consulting fees from Eli Lilly and Company; grant support, provided to his 
      institution, and consulting fees and speaker fees from Tandem Diabetes Care; 
      grant support, provided to his institution, and advisory board fees from 
      Medtronic; grant support and supplies, provided to his institution, from Insulet; 
      and supplies, provided to his institution, from Dexcom. A.B., M.K., A.L., R.J., 
      E.D., and H.W. are employees and shareholders of Eli Lilly and Company.
EDAT- 2021/02/04 06:00
MHDA- 2022/03/29 06:00
PMCR- 2021/06/29
CRDT- 2021/02/03 20:05
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2021/02/03 20:05 [entrez]
PHST- 2021/06/29 00:00 [pmc-release]
AID - 10.1089/dia.2020.0619 [pii]
AID - 10.1089/dia.2020.0619 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2021 Jul;23(7):512-516. doi: 10.1089/dia.2020.0619. Epub 
      2021 Feb 18.